DAFTAR PUSTAKA

Aboyans, V., McClelland, R. L., Allison, M. A., McDermott, M. M., Blumenthal, R. S., Macura, K. Criqui, M. H. 2011. Lower extremity peripheral artery disease in the absence of traditional risk factors. The Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis*, 214**:** 169-173.

Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., Espinola-Klein, C., Kahan, T., Kownator, S., Mazzolai, L., Naylor, A. R., Roffi, M., Röther, J., Sprynger, M., Tendera, M., Tepe, G., Venermo, M., Vlachopoulos, C., Desormais, I. Group, E. S. C. S. D. 2018. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *European Heart Journal*, 39**:** 763-816.

Allen, J. D., Stabler, T., Kenjale, A., Ham, K. L., Robbins, J. L., Duscha, B. D., Dobrosielski, D. A. Annex, B. H. 2010. Plasma nitrite flux predicts exercise performance in peripheral arterial disease after 3months of exercise training. *Free Radic Biol Med*, 49**:** 1138-44.

Aly, S. A., Hossain, M., Bhuiyan, M. A., Nakamura, T. Nagatomo, T. 2009. Assessment of binding affinity to 5-hydroxytryptamine 2A (5-HT2A) receptor and inverse agonist activity of naftidrofuryl: comparison with those of sarpogrelate. *J Pharmacol Sci*, 110**:** 445-50.

Anderson, T. J., Gerhard, M. D., Meredith, I. T., Charbonneau, F., Delagrange, D., Creager, M. A., Selwyn, A. P. Ganz, P. 1995. Systemic nature of endothelial dysfunction in atherosclerosis. *Am J Cardiol*, 75**:** 71b-74b.

Arosio, E., De Marchi, S., Zannoni, M., Prior, M. Lechi, A. 2002. Effect of glutathione infusion on leg arterial circulation, cutaneous microcirculation, and pain-free walking distance in patients with peripheral obstructive arterial disease: a randomized, double-blind, placebo-controlled trial. *Mayo Clin Proc*, 77**:** 754-9.

Bates, D. O. 2010. Vascular endothelial growth factors and vascular permeability. *Cardiovascular research*, 87**:** 262-271.

Bauer, T. A., Regensteiner, J. G., Brass, E. P. Hiatt, W. R. 1999. Oxygen uptake kinetics during exercise are slowed in patients with peripheral arterial disease. *J Appl Physiol (1985)*, 87**:** 809-16.

Beckman, J. A. Creager, M. A. 2013. Chapter 18 - Peripheral Artery Disease: Clinical Evaluation. *In:* Creager, M. A., Beckman, J. A. Loscalzo, J. (eds.) *Vascular Medicine: A Companion to Braunwald's Heart Disease (Second Edition)*. Philadelphia: W.B. Saunders.

Bierhansl, L., Conradi, L.-C., Treps, L., Dewerchin, M. Carmeliet, P. 2017. Central Role of Metabolism in Endothelial Cell Function and Vascular Disease. *Physiology (Bethesda, Md.)*, 32**:** 126-140.

Bode-Boger, S. M., Boger, R. H., Alfke, H., Heinzel, D., Tsikas, D., Creutzig, A., Alexander, K. Frolich, J. C. 1996. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. *Circulation*, 93**:** 85-90.

Bonaca, M. P., Scirica, B. M., Creager, M. A., Olin, J., Bounameaux, H., Dellborg, M., Lamp, J. M., Murphy, S. A., Braunwald, E. Morrow, D. A. 2013. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. *Circulation*, 127**:** 1522-9, 1529e1-6.

Boushel, R., Langberg, H., Gemmer, C., Olesen, J., Crameri, R., Scheede, C., Sander, M. Kjaer, M. 2002. Combined inhibition of nitric oxide and prostaglandins reduces human skeletal muscle blood flow during exercise. *The Journal of physiology*, 543**:** 691-698.

Brass, E. P., Hiatt, W. R., Gardner, A. W. Hoppel, C. L. 2001. Decreased NADH dehydrogenase and ubiquinol-cytochrome c oxidoreductase in peripheral arterial disease. *Am J Physiol Heart Circ Physiol*, 280**:** H603-9.

Brevetti, G., Silvestro, A., Schiano, V. Chiariello, M. 2003. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. *Circulation*, 108**:** 2093-8.

Cantor, W. J., Goodman, S. G., Cannon, C. P., Murphy, S. A., Charlesworth, A., Braunwauld, E. Langer, A. 2005. Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial. *Am Heart J*, 149**:** 275-83.

Chi, Y. W., Lavie, C. J., Milani, R. V. White, C. J. 2008. Safety and efficacy of cilostazol in the management of intermittent claudication. *Vasc Health Risk Manag*, 4**:** 1197-203.

Cooke, J. P. Wilson, A. M. 2010. Biomarkers of peripheral arterial disease. *Journal of the American College of Cardiology*, 55**:** 2017-2023.

Creager, M. A. 2001. Medical management of peripheral arterial disease. *Cardiol Rev*, 9**:** 238-45.

Criqui, M. H. Aboyans, V. 2015. Epidemiology of Peripheral Artery Disease. 116**:** 1509-1526.

De Backer, T., Vander Stichele, R., Lehert, P. Van Bortel, L. 2009. Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data. *Bmj*, 338**:** b603.

de Berrazueta, J. R., Sampedro, I., Garcia-Unzueta, M. T., Llorca, J., Bustamante, M. Amado, J. A. 2003. Effect of transdermal nitroglycerin on inflammatory mediators in patients with peripheral atherosclerotic vascular disease. *Am Heart J*, 146**:** E14.

de Haro Miralles, J., Martinez-Aguilar, E., Florez, A., Varela, C., Bleda, S. Acin, F. 2009. Nitric oxide: link between endothelial dysfunction and

inflammation in patients with peripheral arterial disease of the lower limbs. *Interact Cardiovasc Thorac Surg,* 9**:** 107-12.

Diehm, C., Schuster, A., Allenberg, J. R., Darius, H., Haberl, R., Lange, S., Pittrow, D., von Stritzky, B., Tepohl, G. Trampisch, H. J. 2004. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. *Atherosclerosis,* 172**:** 95-105.

Dormandy, J. A. Rutherford, R. B. 2000. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). *J Vasc Surg,* 31**:** S1-s296.

Earnshaw, J. J., Whitman, B. Foy, C. 2004. National Audit of Thrombolysis for Acute Leg Ischemia (NATALI): clinical factors associated with early outcome. *J Vasc Surg,* 39**:** 1018-25.

Eliason, J. L., Wainess, R. M., Proctor, M. C., Dimick, J. B., Cowan, J. A., Jr., Upchurch, G. R., Jr., Stanley, J. C. Henke, P. K. 2003. A national and single institutional experience in the contemporary treatment of acute lower extremity ischemia. *Annals of surgery,* 238**:** 382-390.

Falconer, D., Papageorgiou, N., Salem, K., Lim, W. Y., Katsargyris, A., Avgerinos, E. Tousoulis, D. 2018. Nitric oxide donors for peripheral artery disease. *Curr Opin Pharmacol,* 39**:** 77-85.

Feron, O., Dessy, C., Moniotte, S., Desager, J. P. Balligand, J. L. 1999. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. *The Journal of clinical investigation,* 103**:** 897-905.

Fowkes, F. G., Housley, E., Cawood, E. H., Macintyre, C. C., Ruckley, C. V. Prescott, R. J. 1991. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. *Int J Epidemiol,* 20**:** 384-92.

Fowkes, F. G. R., Rudan, D., Rudan, I., Aboyans, V., Denenberg, J. O., McDermott, M. M., Norman, P. E., Sampson, U. K. A., Williams, L. J., Mensah, G. A. Criqui, M. H. 2013. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. *The Lancet,* 382**:** 1329-1340.

Gerhard-Herman, M., Gardin, J. M., Jaff, M., Mohler, E., Roman, M. Naqvi, T. Z. 2006. Guidelines for noninvasive vascular laboratory testing: a report from the American Society of Echocardiography and the Society for Vascular Medicine and Biology. *Vasc Med,* 11**:** 183-200.

Gordon, M. B., Jain, R., Beckman, J. A. Creager, M. A. 2002. The contribution of nitric oxide to exercise hyperemia in the human forearm. *Vasc Med,* 7**:** 163-8.

Green, D. J., Dawson, E. A., Groenewoud, H. M., Jones, H. Thijssen, D. H. 2014. Is flow-mediated dilation nitric oxide mediated?: A meta-analysis. *Hypertension,* 63**:** 376-82.

Guo, X., Oldham, M. J., Kleinman, M. T., Phalen, R. F. Kassab, G. S. 2006. Effect of cigarette smoking on nitric oxide, structural, and mechanical properties of mouse arteries. *Am J Physiol Heart Circ Physiol,* 291**:** H2354-61.

Hamburg, N. M. Balady, G. J. 2011. Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits. *Circulation,* 123**:** 87-97.

Hashimoto, A., Miyakoda, G., Hirose, Y. Mori, T. 2006. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. *Atherosclerosis,* 189**:** 350-7.

Heras, M. Chamorro, A. 2000. Atherosclerosis: a systemic condition that requires a global approach. *Eur Heart J,* 21**:** 872-3.

Herman, A. G. Moncada, S. 2005. Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis. *Eur Heart J,* 26**:** 1945-55.

Hermann, M., Flammer, A. Luscher, T. F. 2006. Nitric oxide in hypertension. *J Clin Hypertens (Greenwich),* 8**:** 17-29.

Hiatt, W. R. Brass, E. P. 2013. Chapter 17 - Pathophysiology of Peripheral Artery Disease, Intermittent Claudication, and Critical Limb Ischemia. *In:* Creager, M. A., Beckman, J. A. Loscalzo, J. (eds.) *Vascular Medicine: A Companion to Braunwald's Heart Disease (Second Edition).* Philadelphia: W.B. Saunders.

Hirsch, A. T., Criqui, M. H., Treat-Jacobson, D., Regensteiner, J. G., Creager, M. A., Olin, J. W., Krook, S. H., Hunninghake, D. B., Comerota, A. J., Walsh, M. E., McDermott, M. M. Hiatt, W. R. 2001. Peripheral arterial disease detection, awareness, and treatment in primary care. *Jama,* 286**:** 1317-24.

Hirsch, A. T., Haskal, Z. J., Hertzer, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., Hiratzka, L. F., Murphy, W. R., Olin, J. W., Puschett, J. B., Rosenfield, K. A., Sacks, D., Stanley, J. C., Taylor, L. M., Jr., White, C. J., White, J., White, R. A., Antman, E. M., Smith, S. C., Jr., Adams, C. D., Anderson, J. L., Faxon, D. P., Fuster, V., Gibbons, R. J., Hunt, S. A., Jacobs, A. K., Nishimura, R., Ornato, J. P., Page, R. L. Riegel, B. 2006. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *Circulation,* 113**:** e463-654.

Honing, M. L., Morrison, P. J., Banga, J. D., Stroes, E. S. Rabelink, T. J. 1998. Nitric oxide availability in diabetes mellitus. *Diabetes Metab Rev,* 14**:** 241-9.

Jansen, R., Niemeyer, M. G., Cleophas, T. J. Zwinderman, A. H. 2000. Factors influencing efficacy of nitrate therapy for stable angina pectoris: a multiple linear regression analysis. *Angiology,* 51**:** 1007-12.

Kalbaugh, C. A., Kucharska-Newton, A., Wruck, L., Lund, J. L., Selvin, E., Matsushita, K., Bengtson, L. G. S., Heiss, G. Loehr, L. 2017. Peripheral Artery Disease Prevalence and Incidence Estimated From Both Outpatient and Inpatient Settings Among Medicare Fee-for-Service Beneficiaries in the Atherosclerosis Risk in Communities (ARIC) Study. *Journal of the American Heart Association,* 6**:** e003796.

Kashyap, V. S., Lakin, R. O., Campos, P., Allemang, M., Kim, A., Sarac, T. P., Hausladen, A. Stamler, J. S. 2017. The LargPAD Trial: Phase IIA evaluation of l-arginine infusion in patients with peripheral arterial disease. *J Vasc Surg,* 66**:** 187-194.

Katzung, B. G. 2007. Basic & clinical pharmacology. Lange Medical Books/McGraw Hill. New York.

Kenjale, A. A., Ham, K. L., Stabler, T., Robbins, J. L., Johnson, J. L., Vanbruggen, M., Privette, G., Yim, E., Kraus, W. E. Allen, J. D. 2011. Dietary nitrate supplementation enhances exercise performance in peripheral arterial disease. *J Appl Physiol (1985),* 110**:** 1582-91.

Klahr, S. 2001. The role of nitric oxide in hypertension and renal disease progression. *Nephrol Dial Transplant,* 16 Suppl 1**:** 60-2.

Koo, T. K. Li, M. Y. 2016. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. *Journal of chiropractic medicine,* 15**:** 155-163.

Kullo, I. J. Leeper, N. J. 2015. The genetic basis of peripheral arterial disease: current knowledge, challenges, and future directions. *Circulation research,* 116**:** 1551-1560.

Kumar, S., Singh, R. K. Bhardwaj, T. R. 2017. Therapeutic role of nitric oxide as emerging molecule. *Biomed Pharmacother,* 85**:** 182-201.

Lidder, S. Webb, A. J. 2013. Vascular effects of dietary nitrate (as found in green leafy vegetables and beetroot) via the nitrate-nitrite-nitric oxide pathway. *Br J Clin Pharmacol,* 75**:** 677-96.

Lilly, L. S. 2011, *Pathophysiology of heart disease : a collaborative project of medical students and faculty*. Wolters Kluwer/Lippincott Williams & Wilkins, Baltimore, MD.

Loffredo, L., Pignatelli, P., Cangemi, R., Andreozzi, P., Panico, M. A., Meloni, V. Violi, F. 2006. Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: Effect of an antioxidant treatment. *Journal of Vascular Surgery,* 44**:** 525-530.

Ma, A., Garland, W. T., Smith, W. B., Skettino, S., Navarro, M. T., Chan, A. Q., Anderson, B. E. Cooke, J. P. 2006. A pilot study of ranolazine in patients with intermittent claudication. *Int Angiol,* 25**:** 361-9.

Martinez, C. A., Carmeli, E., Barak, S. Stopka, C. B. 2009. Changes in pain-free walking based on time in accommodating pain-free exercise therapy for peripheral arterial disease. *Journal of Vascular Nursing,* 27**:** 2-7.

Matsunaga, T., Warltier, D. C., Weihrauch, D. W., Moniz, M., Tessmer, J. Chilian, W. M. 2000. Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. *Circulation,* 102**:** 3098-103.

McDermott, M. M., Guralnik, J. M., Criqui, M. H., Liu, K., Kibbe, M. R. Ferrucci, L. 2014. Six-minute walk is a better outcome measure than treadmill walking tests in therapeutic trials of patients with peripheral artery disease. *Circulation,* 130**:** 61-8.

McDermott, M. M., Guralnik, J. M., Greenland, P., Pearce, W. H., Criqui, M. H., Liu, K., Taylor, L., Chan, C., Sharma, L., Schneider, J. R., Ridker, P. M., Green, D. Quann, M. 2003. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. *Circulation,* 107**:** 757-61.

McDermott, M. M., Mehta, S. Greenland, P. 1999. Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. *Arch Intern Med,* 159**:** 387-92.

McKinley-Barnard, S., Andre, T., Morita, M. Willoughby, D. S. 2015. Combined L-citrulline and glutathione supplementation increases the concentration of markers indicative of nitric oxide synthesis. *Journal of the International Society of Sports Nutrition,* 12**:** 27-27.

Meijer, W. T., Hoes, A. W., Rutgers, D., Bots, M. L., Hofman, A. Grobbee, D. E. 1998. Peripheral arterial disease in the elderly: The Rotterdam Study. *Arterioscler Thromb Vasc Biol,* 18**:** 185-92.

Moher, D., Jones, A., Lepage, L. for the, C. G. 2001. Use of the consort statement and quality of reports of randomized trials: A comparative before-and-after evaluation. *JAMA,* 285**:** 1992-1995.

Mohler, E. R., Hiatt, W. R., Gornik, H. L., Kevil, C. G., Quyyumi, A., Haynes, W. G. Annex, B. H. 2014. Sodium nitrite in patients with peripheral artery disease and diabetes mellitus: safety, walking distance and endothelial function. *Vasc Med,* 19**:** 9-17.

Mueller, T., Hinterreiter, F., Luft, C., Poelz, W., Haltmayer, M. Dieplinger, B. 2014. Mortality rates and mortality predictors in patients with symptomatic peripheral artery disease stratified according to age and diabetes. *Journal of Vascular Surgery,* 59**:** 1291-1299.

Newton, D. J., Khan, F., Kennedy, G. Belch, J. J. 2008. Improvement in systemic endothelial condition following amputation in patients with critical limb ischemia. *Int Angiol,* 27**:** 408-12.

Norgren, L., Hiatt, W. R., Dormandy, J. A., Nehler, M. R., Harris, K. A. Fowkes, F. G. R. 2007. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *Journal of Vascular Surgery,* 45**:** S5-S67.

Opie, L. H. Gersh, B. J. 2013, *Drugs for the heart*. Elsevier Saunders, Philadelphia, PA.

Park, S. J., Ahn, J. M. Kang, S. J. 2011. Paradigm shift to functional angioplasty: new insights for fractional flow reserve- and intravascular ultrasound-guided percutaneous coronary intervention. *Circulation,* 124**:** 951-7.

Patel, M. R., Conte, M. S., Cutlip, D. E., Dib, N., Geraghty, P., Gray, W., Hiatt, W. R., Ho, M., Ikeda, K., Ikeno, F., Jaff, M. R., Jones, W. S., Kawahara, M., Lookstein, R. A., Mehran, R., Misra, S., Norgren, L., Olin, J. W., Povsic, T. J., Rosenfield, K., Rundback, J., Shamoun, F., Tcheng, J., Tsai, T. T., Suzuki, Y., Vranckx, P., Wiechmann, B. N., White, C. J., Yokoi, H.

Krucoff, M. W. 2015. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). *Journal of the American College of Cardiology*, 65**:** 931-941.

Porth, C. M. 2009, *Pathophysiology : concepts of altered health states*. Wolters Kluwer Health/Lippincott Williams & Wilkins, [Philadelphia, Pa.].

Rajendran, P., Rengarajan, T., Thangavel, J., Nishigaki, Y., Sakthisekaran, D., Sethi, G. Nishigaki, I. 2013. The vascular endothelium and human diseases. *International journal of biological sciences,* 9**:** 1057-1069.

Regensteiner, J. G. Hiatt, W. R. 2002. Current medical therapies for patients with peripheral arterial disease: a critical review. *Am J Med,* 112**:** 49-57.

Robbins, S. L., Kumar, V. Cotran, R. S. 2010, *Robbins and Cotran pathologic basis of disease*. Saunders/Elsevier, Philadelphia, PA.

Sampson, U. K., Fowkes, F. G., McDermott, M. M., Criqui, M. H., Aboyans, V., Norman, P. E., Forouzanfar, M. H., Naghavi, M., Song, Y., Harrell, F. E., Jr., Denenberg, J. O., Mensah, G. A., Ezzati, M. Murray, C. 2014. Global and regional burden of death and disability from peripheral artery disease: 21 world regions, 1990 to 2010. *Glob Heart,* 9**:** 145-158.e21.

Sanada, H., Higashi, Y., Goto, C., Chayama, K., Yoshizumi, M. Sueda, T. 2005. Vascular function in patients with lower extremity peripheral arterial disease: a comparison of functions in upper and lower extremities. *Atherosclerosis*, 178**:** 179-85.

Shahin, Y., Cockcroft, J. R. Chetter, I. C. 2013. Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication. *Br J Surg*, 100**:** 1154-63.

Singh, V., Rana, R. K. Singhal, R. 2013. Analysis of repeated measurement data in the clinical trials. *Journal of Ayurveda and integrative medicine,* 4**:** 77-81.

St-Pierre, A., Cantin, B., Lamarche, B., Auger, D., Després, J.-P. Dagenais, G. R. 2010. Intermittent claudication: From its risk factors to its long-term prognosis in men. The Quebec Cardiovascular Study. *The Canadian journal of cardiology*, 26**:** 17-21.

Stewart, K. J. 2002. Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. *Jama,* 288**:** 1622-31.

Stoeckelhuber, B. M., Suttmann, I., Stoeckelhuber, M. Kueffer, G. 2003. Comparison of the Vasodilating Effect of Nitroglycerin, Verapamil, and Tolazoline in Hand Angiography. *Journal of Vascular and Interventional Radiology*, 14**:** 749-754.

Storer, B. E. 1989. Design and analysis of phase I clinical trials. *Biometrics,* 45**:** 925-37.

Szuba, A., Oka, R. K., Harada, R. Cooke, J. P. 2006. Limb hemodynamics are not predictive of functional capacity in patients with PAD. *Vasc Med,* 11**:** 155-63.

Taddei, S., Galetta, F., Virdis, A., Ghiadoni, L., Salvetti, G., Franzoni, F., Giusti, C. Salvetti, A. 2000. Physical Activity Prevents Age-Related Impairment in Nitric Oxide Availability in Elderly Athletes. 101**:** 2896-2901.

Tidball, J. G., Spencer, M. J., Wehling, M. Lavergne, E. 1999. Nitric-oxide synthase is a mechanical signal transducer that modulates talin and vinculin expression. *J Biol Chem*, 274**:** 33155-60.

Toprakci, M., Ozmen, D., Mutaf, I., Turgan, N., Parildar, Z., Habif, S., Guner, I. Bayindir, O. 2000. Age-associated changes in nitric oxide metabolites nitrite and nitrate. *Int J Clin Lab Res*, 30**:** 83-5.

Vallance, P. Chan, N. 2001. Endothelial function and nitric oxide: clinical relevance. *Heart (British Cardiac Society)*, 85**:** 342-350.

Van Belle, E., Nikol, S., Norgren, L., Baumgartner, I., Driver, V., Hiatt, W. R. Belch, J. 2011. Insights on the role of diabetes and geographic variation in patients with critical limb ischaemia. *Eur J Vasc Endovasc Surg*, 42**:** 365-73.

Walker, M. A., Hoier, B., Walker, P. J., Schulze, K., Bangsbo, J., Hellsten, Y. Askew, C. D. 2016. Vasoactive enzymes and blood flow responses to passive and active exercise in peripheral arterial disease. *Atherosclerosis*, 246**:** 98-105.

Walker, S. R., Tennant, S. MacSweeney, S. T. 1998. A randomized, double-blind, placebo-controlled, crossover study to assess the immediate effect of sublingual glyceryl trinitrate on the ankle brachial pressure index, claudication, and maximum walking distance of patients with intermittent claudication. *J Vasc Surg*, 28**:** 895-900.

Wang, H., Hiatt, W. R., Barstow, T. J. Brass, E. P. 1999. Relationships between muscle mitochondrial DNA content, mitochondrial enzyme activity and oxidative capacity in man: alterations with disease. *Eur J Appl Physiol Occup Physiol*, 80**:** 22-7.

Wattanakit, K., Williams, J. E., Schreiner, P. J., Hirsch, A. T. Folsom, A. R. 2005. Association of anger proneness, depression and low social support with peripheral arterial disease: the Atherosclerosis Risk in Communities Study. *Vasc Med*, 10**:** 199-206.

Weiss, R. 2006. Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. *Vascular health and risk management*, 2**:** 303-308.

Williams, G., Shi-Wen, X., Abraham, D., Selvakumar, S., Baker, D. M. Tsui, J. C. S. 2012. Nitric oxide manipulation: a therapeutic target for peripheral arterial disease? *Cardiology research and practice*, 2012**:** 656247-656247.

Woessner, M. N., VanBruggen, M. D., Pieper, C. F., O'Reilly, E. K., Kraus, W. E. Allen, J. D. 2017. Combined Dietary Nitrate and Exercise Intervention in Peripheral Artery Disease: Protocol Rationale and Design. *JMIR Res Protoc*, 6**:** e139.

Yustikasari, I., Aprami, T. M., Tedjokusumo, P., Purnomowati, A. Agustian, D. 2015. TCTAP A-131 Correlation Between Traditional Cardiovascular Risk Factors and Complexity of Coronary Artery Lesion Determined by SYNTAX Score in Patient with ST-Elevation Myocardial Infarction. 65**:** S65.